+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast To 2027

  • ID: 5147079
  • Report
  • September 2020
  • Region: Global
  • 601 Pages
  • IQ4I Research & Consultancy Pvt. Ltd

FEATURED COMPANIES

  • Alpha Tau Medical
  • Clarity’S Pharmaceuticals
  • Ge Company
  • Isoscience, LLC
  • Nukem Isotopes, GmbH
  • Rosatom (Jsc Isotope)
  • MORE

Over the past 50 years, the nuclear medicine field has displayed a strong link between investments in chemistry and the development of radionuclide and radio-labeled compounds which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular levels for probing, tracking tissue function, study disease progression and assessing treatment responses.

The nuclear medicine global market is poised to grow at a high single digit CAGR from 2020 to 2027 to reach $10,742.7 million by 2027.

Increasing radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.

The nuclear medicinal market is classified based on modality into diagnosis and therapeutics. The diagnostics market commanded the largest market revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to an increase in SPECT and PET procedures. The therapeutics segment is projected to grow at high teen CAGR from 2020 to 2027 due to technological advancements in the targeted treatment of cancers. Potential new radioisotopes in the pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market commanded the largest revenue in 2020 and is expected to grow at low single digit CAGR from 2020 to 2027 due to an increase in TC-99m isotope applications and product approvals. Among SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Xenon (Xe-133), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for the largest share in 2020 and is projected to grow at a mid single digit CAGR from 2020 to 2027 due to its extensive usage in various diagnostic applications and emerging sources to meet the demand. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for the largest share in 2020 and is expected to grow at mid single digit CAGR from 2020 to 2027 due to an increase in the number of cardiac imaging cases using Tc-99m. Oncology is expected to grow at mid single digit CAGR from 2020 to 2027 due to increasing expanding usage in early screening tests in vulnerable populations in various developed countries.

PET is the fastest-growing segment with mid single digit CAGR from 2020 to 2027 due to an increase in the adoption of cyclotron for the production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027. Gallium (Ga-68) is expected to grow at high double digit CAGR from 2020 to 2027 due to an increase in usage as theranostic pair in assessing the suitability of patient for Lutathera and many emerging targeted radiotherapy agents. PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for the largest share in 2020 and is projected to grow at high single digit CAGR from 2020 to 2027 due to an increase in the patient pool of lung, thyroid, brain breast cancer and dementia related conditions.

The therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy.

Beta radiation accounted for the largest share of in 2020 and is projected to grow at high double digit CAGR of from 2020 to 2027. Beta radiation therapy by isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. Lu-177 commanded the largest share in 2020 and is expected to grow at high double digit CAGR from 2020 to 2027 due to increased adoption of Lu-177 based radiopharmaceuticals for the treatment of neuroendocrine tumor and anticipated launch of new treatment products based on the isotope. Strontium (Sr-89) is expected to grow at a strong CAGR from 2020 to 2027. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others. I-125 market accounted for the largest share in 2020 and is projected to grow at low single digit CAGR from 2020 to 2027 due to increasing usage in the treatment of lung cancer, prostate cancer, eye-related disease (retinoblastoma and eye plaque) and brain cancer. Therapeutic nuclear medicine by application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors (GEP-NETs), metastatic bone cancer, breast cancer and others. The GEP-NETs market accounted for the largest share in 2020 and is expected to grow at high double digit CAGR from 2020 to 2027. Prostate Cancer is expected to grow at a strong CAGR from 2020 to 2027 due to advanced clinical trial stage (phase 3) and predicted launch of Lu-177 PSMA-617 product in 2021.

Nuclear medicine based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers and others. Hospital accounted for the largest share in 2020 and is projected to grow at high double digit CAGR from 2020 to 2027 due to the ready availability of cyclotrons for the generation of isotope and use of advanced hybrid imaging.

The stable isotope global market is expected to grow at low single digit CAGR from 2020 to 2027 to reach $284.3 million by 2027.

The Nuclear Medicine market includes stable isotopes are classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), Sulphur (S-32) and others. Deuterium (D-2) accounted the largest share n 2020 and is the fastest-growing market with a projected CAGR of 3.3% from 2020 to 2027 due to the use of deuterium as a dietary supplement of deuterium-depleted water which helps to extend the survival rate of lung cancer patient via exerting anticancer effect and modification of deuterium leads to the development of novel, highly differentiated drugs which have therapeutic applications in diabetic nephropathy, hot flashes, spasticity, neuropathic pain and multiple melanomas. The stable isotope applications market is segmented into diagnostics-therapy, pharmaceutical companies and others. The diagnostics and therapy market commanded the largest market revenue in 2020 and is expected grow at low single digit CAGR from 2020 to 2027 due to use in diagnosis and treatment of pancreas, liver and intestine related disorders. The pharmaceuticals is the fastest-growing segment at low single digit CAGR from 2020 to 2027 due to novel developments in the utilization of stable isotopes that involve biopolymers, where isotope-labeled species are generated from cells grown on labeled growth media.

Geographical wise, North American region commanded the largest revenue in 2020 and is expected to grow at low single digit CAGR from 2020 to 2027. The growing use of SPECT and PET scans, technological advancements in equipment, increased utilization of fusion imaging, increasing awareness of radiopharmaceuticals among radiologists, alpha radio-immunotherapy-based targeted cancer treatment are driving the market.

Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer Group (Germany), GE Healthcare (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), and Fujifilm Holding Corporation (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alpha Tau Medical
  • Clarity’S Pharmaceuticals
  • Ge Company
  • Isoscience, LLC
  • Nukem Isotopes, GmbH
  • Rosatom (Jsc Isotope)
  • MORE

1 Executive Summary

2 Introduction
2.1 Key Take Away
2.2 Report Scope
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology
2.6.1 Market Size Estimation
2.6.2 Market Crackdown and Data Triangulation
2.6.3 Secondary Sources
2.6.4 Primary Sources
2.6.5 Key Data Points from Secondary Sources
2.6.6 Key Data Points from Primary Sources
2.6.7 Assumptions

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers and Opportunities
3.3.1.1 Increasing Applications of Radiopharmaceuticals
3.3.1.2 Production of Radiopharmaceuticals from Cyclotrons
3.3.1.3 Efficient Diagnosis and Treatments
3.3.1.4 Increasing Interest in Theranostics
3.3.1.5 Rise in Public Awareness
3.3.1.6 Technological Advancements
3.3.1.7 Increasing Demand in Emerging Markets
3.3.2 Restraints and Threats
3.3.2.1 the Shorter Half-Life of Radiopharmaceuticals
3.3.2.2 High Cost and Supply Shortage of Isotopes
3.3.2.3 Radio Toxicity
3.3.2.4 Shortage of Qualified Technicians
3.3.2.5 Withdrawal of Radiopharmacy Products Due to Limited Commercial Adoption
3.3.2.6 Regulatory Issues
3.3.2.7 Threat from Traditional/Alternative Diagnostic Procedures
3.3.2.8 Huge Capital Investment
3.4 Problem Areas
3.4.1 Closure of Reactors
3.5 Winning Imperatives
3.5.1 Availability of Technetium
3.6 Regulatory Guidelines
3.6.1 United States
3.6.2 Europe
3.6.3 Japan
3.6.4 India
3.6.5 China
3.6.6 South Korea
3.7 Reimbursement Scenario and Challenges
3.8 Clinical Trials
3.9 Emerging Isotopes
3.10 Technological Advancements
3.10.1 Compton Camera
3.10.2 Subtle Pet
3.10.3 Production of Isotopes Throguh Cyclotrons
3.10.4 Linac Based Tc-99M Production
3.10.5 Auger Electrons
3.11 Supply Chain Analysis of Nuclear Medicine
3.11.1 Reactors
3.11.2 Cyclotron
3.11.3 Generators
3.11.4 Linac Based Tc-99M Production Method
3.11.5 Processing Facility
3.11.6 Hospitals and Central Radio Pharmacies
3.11.7 Supply Chain Analysis of Lutitium-177 (Lu-177)
3.11.8 Supply Chain Analysis of Gallium-68 (Ga-68)
3.11.9 Supply Chain Analysis of Actinium-225 (Ac-225) and Bismuth-213 (Bi-213)
3.11.10 Supply Chain Analysis of Rubidium (Rb-82) and Strontium-82 (Sr-82)
3.11.11 Supply Chain Analysis of Radium-223 (Ra-223)
3.12 List of Potential New Reactors
3.13 List of Fda Approved Radiopharmaceuticals
3.14 Porter's Five Force Analysis
3.14.1 Threat of New Entrants
3.14.2 Threat of Substitutes
3.14.3 Competitive Rivalry
3.14.4 Bargaining Power of Suppliers
3.14.5 Bargaining Power of Buyers
3.15 Market Share Analysis by Major Players
3.15.1 Nuclear Medicine Market
3.15.2 Spect Market
3.15.3 Pet Market
3.15.4 Nuclear Medicine Therapeutic Market
3.15.5 Tc-99 Market
3.15.6 F-18 Market
3.15.7 Ga-68 Market
3.15.8 Rb-82 Market
3.16 Nuclear Medicine-Funding Scenario
3.17 Nuclear Medicine – Deals and Approvals

4 Nuclear Medicine Global Market, by Modality
4.1 Introduction
4.2 Diagnostics
4.2.1 Nuclear Medicine for Diagnosis, by Isotopes
4.2.1.1 Spect, by Isotopes
4.2.1.1.1 Technetium (Tc-99M)
4.2.1.1.2 Thallium (Tl-201)
4.2.1.1.3 Gallium (Ga-67)
4.2.1.1.4 Iodine (I-123)
4.2.1.1.5 Samarium (Sm-153)
4.2.1.1.6 Xenon (Xe-133)
4.2.1.1.7 Rhenium (Re-186)
4.2.1.1.8 Others (In-111, Y-90, Cr-51)
4.2.1.2 Pet, by Isotopes
4.2.1.2.1 Fluorodeoxyglucose (18F-Fdg)
4.2.1.2.2 Gallium (Ga-68)
4.2.1.2.3 Rubidium (Rb-82)
4.2.1.2.4 Others (C-11, N-13, Cu-64, Zr-89)
4.2.2 Nuclear Medicine for Diagnosis, by Application
4.2.2.1 Spect by Application
4.2.2.1.1 Cardiology
4.2.2.1.2 Pulmonary
4.2.2.1.3 Oncology
4.2.2.1.4 Nephrology
4.2.2.1.5 Neurology
4.2.2.1.6 Inflammation
4.2.2.1.7 Thyroid Glands
4.2.2.1.8 Lymphology
4.2.2.1.9 Others
4.2.2.2 Pet by Application
4.2.2.2.1 Oncology
4.2.2.2.2 Neurology
4.2.2.2.3 Cardiology
4.2.2.2.4 Inflammation
4.2.2.2.5 Others
4.3 Therapeutics
4.3.1 Nuclear Medicine for Therapeutics, by Radiation Type
4.3.1.1 Beta Radiation Therapy
4.3.1.1.1 Yttrium (Y-90)
4.3.1.1.2 Iodine (I-131)
4.3.1.1.3 Lutetium (Lu-177)
4.3.1.1.4 Samarium (Sm-153)
4.3.1.1.5 Rhenium (Re-186)
4.3.1.1.6 Strontium (Sr-89)
4.3.1.1.7 Erbium (Er-169)
4.3.1.1.8 Others
4.3.1.2 Alpha Radiation Therapy, by Isotopes (Ra-223)
4.3.1.3 Brachytherapy, by Isotopes
4.3.1.3.1 Iodine (I-125)
4.3.1.3.2 Cesium (Cs-131)
4.3.1.3.3 Iridium (Ir-192)
4.3.1.3.4 Palladium (Pd-103)
4.3.1.3.5 Others
4.3.1.4 Nuclear Medicine Therapeutics, by Application
4.3.1.5 Prostate Cancer
4.3.1.6 Thyroid Cancer
4.3.1.7 Liver Cancer
4.3.1.8 Gep-Net Therapeutics
4.3.1.9 Metastatic Bone Cancer Therapeutics
4.3.1.10 Breast Cancer Therapeutics
4.3.1.11 Other Applications

5 Nuclear Medicine Global Market, by End-Users
5.1 Introduction
5.2 Hospital
5.3 Ambulatory Centers
5.4 Diagnostic Centers
5.5 Other End-Users

6 Stable Isotopes
6.1 Introduction
6.2 Market Analysis
6.2.1 Factors Influencing Market
6.2.2 Drivers and Opportunities
6.2.2.1 Increase in Research Activities (Pharmaceuticals and Biotechnology Sectors)
6.2.2.2 Increasing Applications
6.2.3 Restraints and Threats
6.2.3.1 High Cost of Stable Isotopes
6.2.3.2 Stable Isotopes-Side Effects and Safety Issues
6.2.3.3 Stringent Regulations for Manufacturing and Use of Stable Isotopes
6.3 Stable Isotopes Market, by Isotope
6.3.1 Carbon (C-13)
6.3.2 Deuterium (D2)
6.3.3 Oxygen (O-18)
6.3.4 Nitrogen (N-15)
6.3.5 Sulphur (S-32)
6.3.6 Others
6.4 Stable Isotopes Market, by Application
6.4.1 Introduction
6.4.2 Diagnostics and Therapy
6.4.3 Pharmaceuticals
6.4.4 Others
6.5 Stable Isotopes Market, by Geography
6.5.1 Introduction
6.5.2 North America
6.5.3 Europe
6.5.4 Asia-Pacific
6.5.5 Rest of the World

7 Nuclear Medicine Global Market by Region
7.1 Introduction
7.2 North America
7.2.1 U.S.
7.2.2 Rest of N.A.
7.3 Europe
7.3.1 Germany
7.3.2 France
7.3.3 Italy
7.3.4 Rest of E.U.
7.4 APAC
7.4.1 Japan
7.4.2 China
7.4.3 South Korea
7.4.4 Rest of APAC
7.5 Rest of the World
7.5.1 Turkey
7.5.2 Brazil
7.5.3 Others

8 Competitive Landscape
8.1 Introduction
8.2 Approvals
8.3 Collaboration
8.4 Acquisition
8.5 Expansion
8.6 Others

9 Major Player Profiles
9.1 Bayer Group
9.1.1 Overview
9.1.2 Financials
9.1.3 Product Portfolio
9.1.4 Key Developments
9.1.5 Business Strategy
9.1.6 SWOT Analysis
9.2 Bracco S.P.A
9.2.1 Overview
9.2.2 Financials
9.2.3 Product Portfolio
9.2.4 Key Developments
9.2.5 Business Strategy
9.2.6 SWOT Analysis
9.3 Cardinal Health Inc.
9.3.1 Overview
9.3.2 Financials
9.3.3 Product Portfolio
9.3.4 Key Developments
9.3.5 Business Strategy
9.3.6 SWOT Analysis
9.4 CDH Investments (CDH Gentech Ltd), (Sirtex Ltd.)
9.4.1 Overview
9.4.2 Financials
9.4.3 Product Portfolio
9.4.4 Key Developments
9.4.5 Business Strategy
9.4.6 SWOT Analysis
9.5 Curium Pharma
9.5.1 Overview
9.5.2 Financials
9.5.3 Product Portfolio
9.5.4 Key Developments
9.5.5 Business Strategy
9.5.6 SWOT Analysis
9.6 Fujifilm Holdings Corporation
9.6.1 Overview
9.6.2 Financials
9.6.3 Product Portfolio
9.6.4 Key Developments
9.6.5 Business Strategy
9.6.6 SWOT Analysis
9.7 GE Healthcare
9.7.1 Overview
9.7.2 Financials
9.7.3 Product Portfolio
9.7.4 Key Developments
9.7.5 Business Strategy
9.7.6 SWOT Analysis
9.8 Jubilant Life Sciences
9.8.1 Overview
9.8.2 Financials
9.8.3 Product Portfolio
9.8.4 Key Developments
9.8.5 Business Strategy
9.8.6 SWOT Analysis
9.9 Lantheus Medical Imaging, Inc.
9.9.1 Overview
9.9.2 Financials
9.9.3 Product Portfolio
9.9.4 Key Developments
9.9.5 Business Strategy
9.9.6 SWOT Analysis
9.10 Novartis International AG
9.10.1 Overview
9.10.2 Financials
9.10.3 Product Portfolio
9.10.4 Key Developments
9.10.5 Business Strategy
9.10.6 SWOT Analysis

List of Tables
Table 1 Nuclear Medicine Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 2 Reimbursement Rates for Radiopharmaceuticals and Diagnostic Imaging Techniques
Table 3 Nuclear Medicine Clinical Trials
Table 4 Nuclear Medicine Emerging Isotopes
Table 5 Technetium (Tc-99M) Reactors
Table 6 Lutetium (Lu-177) Suppliers and Production Capacity
Table 7 Gallium (Ga-68) Generator Suppliers
Table 8 Actinium (Ac-225) Current and Future Suppliers
Table 9 Strontium (Sr-82)/Rubidium (Rb-82) Generator Suppliers
Table 10 New Potential Reactors
Table 11 Fda Approved Radiopharmaceuticals
Table 12 Nuclear Medicine Global Market Revenue, by Modality, 2019-2027 ($Mn)
Table 13 Nuclear Medicine Diagnostic, Therapeutic and Overall Procedural Volume (2020) (Nos.)
Table 14 Nuclear Medicine Diagnostics Global Market Revenue, by Product, 2019-2027 ($Mn)
Table 15 Nuclear Medicine Diagnostics Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 16 Nuclear Medicine Spect Global Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 17 Nuclear Medicine Spect Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 18 Technetium (Tc-99M) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 19 Thallium (Tl-201) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 20 Gallium (Ga-67) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 21 Iodine (I-123) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 22 Samarium (Sm-153) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 23 Xenon (Xe-133) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 24 Rhenium (Re-186) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 25 Other Spect Isotopes Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 26 Nuclear Medicine Pet Global Market Revenue, by Isotopes, 2019-2027 ($Mn)
Table 27 Nuclear Medicine Pet Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 28 Fluorodeoxyglucose (18F-Fdg) Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 29 Gallium (Ga-68) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 30 Production Details of Rb-82
Table 31 Rubidium (Rb-82) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 32 Other Pet Isotopes Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 33 Nuclear Medicine Spect Global Market Revenue, by Application, 2019-2027 ($Mn)
Table 34 Cardiology Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 35 Pulmonary Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 36 Oncology Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 37 Nephrology Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 38 Neurology Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 39 Inflammation Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 40 Thyroid Glands Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 41 Lymphology Spect Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 42 Other Spect Applications Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 43 Nuclear Medicine Pet Global Market Revenue, by Application, 2019-2027 ($Mn)
Table 44 Oncology Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 45 Neurology Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 46 Cardiology Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 47 Inflammation Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 48 Others Pet Application Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 49 Nuclear Medicine Therapeutics Global Market Revenue, by Radiation Type, 2019-2027 ($Mn)
Table 50 Nuclear Medicine Therapeutics Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 51 Beta Radiation Therapy Global Market Revenue, by Isotopes, 2019-2027 ($Mn)
Table 52 Beta Radiation Therapy Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 53 Yttrium (Y-90) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 54 Iodine(I-131) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 55 Lutetium (Lu-177) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 56 Samarium (Sm-153) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 57 Rhenium (Re-186) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 58 Strontium (Sr-89) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 59 Erbium (Er-169) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 60 Other Beta Radiation Therapy Isotopes Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 61 Alpha Radiation Therapy Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 62 Brachytherapy Global Market Revenue, by Isotopes, 2019-2027 ($Mn)
Table 63 Brachytherapy Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 64 Iodine (I-125) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 65 Cesium (Cs-131) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 66 Iridium (Ir-192) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 67 Palladium (Pd-103) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 68 Other Brachytherapy Isotopes Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 69 Nuclear Medicine Therapeutics Global Market Revenue, by Application, 2019-2027 ($Mn)
Table 70 Prostate Cancer Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 71 Thyroid Cancer Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 72 Liver Cancer Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 73 Gep-Net Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 74 Metastatic Bone Cancer Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 75 Breast Cancer Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 76 Other Therapeutic Applications Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 77 Nuclear Medicine Global Market Revenue, by End-Users, 2019-2027 ($Mn)
Table 78 Hospital Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 79 Ambulatory Centers Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 80 Diagnostic Centers End-User Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 81 Other End-User Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 82 Stable Isotopes Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 83 Stable Isotopes Global Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 84 Carbon (C-13) Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 85 Deuterium (D2) Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 86 Oxygen (O-18) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 87 Nitrogen (N-15) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 88 Sulphur (S-32) Isotope Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 89 Other Stable Isotopes Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 90 Stable Isotopes Global Market Revenue, by Application, 2019-2027 ($Mn)
Table 91 Diagnostics-Therapy Application Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 92 Pharmaceuticals Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 93 Others Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 94 Stable Isotopes Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 95 North America Stable Isotopes Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 96 North America Stable Isotopes Market Revenue, by Application, (2020-2027) ($Mn)
Table 97 Europe Stable Isotopes Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 98 Europe Stable Isotopes Market Revenue, by Application, 2019-2027 ($Mn)
Table 99 Asia-Pacific Stable Isotopes Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 100 Asia-Pacific Stable Isotopes Market Revenue, by Application, 2019-2027 ($Mn)
Table 101 Rest of the World Stable Isotopes Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 102 Rest of the World Stable Isotopes Market Revenue, by Application, 2019-2027 ($Mn)
Table 103 Nuclear Medicine Global Market Revenue, by Region, 2019-2027 ($Mn)
Table 104 North America Nuclear Medicine Market Revenue, by Modality, 2019-2027 ($Mn)
Table 105 North America Nuclear Medicine Diagnostics Market Revenue, by Products, 2019-2027 ($Mn)
Table 106 North America Nuclear Medicine Spect Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 107 North America Nuclear Medicine Pet Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 108 North America Nuclear Medicine Spect Market Revenue, by Application, 2019-2027 ($Mn)
Table 109 North America Nuclear Medicine Pet Market Revenue, by Application, 2019-2027 ($Mn)
Table 110 North America Nuclear Medicine Therapeutics Market Revenue, by Radiation Type, 2019-2027 ($Mn)
Table 111 North America Nuclear Medicine Beta Radiation Therapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 112 North America Nuclear Medicine Brachytherapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 113 North America Nuclear Medicine Therapeutics Market Revenue, by Application, 2019-2027 ($Mn)
Table 114 North America Nuclear Medicine Market Revenue, by End-Users, 2019-2027 ($Mn)
Table 115 Europe Nuclear Medicine Market Revenue, by Modality, 2019-2027 ($Mn)
Table 116 Europe Nuclear Medicine Diagnostics Market Revenue, by Products, 2019-2027 ($Mn)
Table 117 Europe Nuclear Medicine Spect Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 118 Europe Nuclear Medicine Pet Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 119 Europe Nuclear Medicine Spect Market Revenue, by Application, 2019-2027 ($Mn)
Table 120 Europe Nuclear Medicine Pet Market Revenue, by Application, 2019-2027 ($Mn)
Table 121 Europe Nuclear Medicine Therapeutics Market Revenue, by Radiation Type, 2019-2027 ($Mn)
Table 122 Europe Nuclear Medicine Beta Radiation Therapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 123 Europe Brachytherapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 124 Europe Nuclear Medicine Therapeutics Market Revenue, by Application, 2019-2027 ($Mn)
Table 125 Europe Nuclear Medicine Market Revenue, by End-Users, 2019-2027 ($Mn)
Table 126 APAC Nuclear Medicine Market Revenue, by Modality, 2019-2027 ($Mn)
Table 127 APAC Nuclear Medicine Diagnostics Market Revenue, by Products, 2019-2027 ($Mn)
Table 128 APAC Nuclear Medicine Spect Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 129 APAC Nuclear Medicine Pet Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 130 APAC Nuclear Medicine Spect Market Revenue, by Application, 2019-2027 ($Mn)
Table 131 APAC Nuclear Medicine Pet Market Revenue, by Application, 2019-2027 ($Mn)
Table 132 APAC Nuclear Medicine Therapeutics Market Revenue, by Radiation Type, 2019-2027 ($Mn)
Table 133 APAC Nuclear Medicine Beta Radiation Therapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 134 APAC Brachytherapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 135 APAC Nuclear Medicine Therapeutics Market Revenue, by Application, 2019-2027 ($Mn)
Table 136 APAC Nuclear Medicine Market Revenue, by End-Users, 2019-2027 ($Mn)
Table 137 Row Nuclear Medicine Market Revenue, by Modality, 2019-2027 ($Mn)
Table 138 Row Nuclear Medicine Diagnostics Market Revenue, by Products, 2019-2027 ($Mn)
Table 139 Row Nuclear Medicine Spect Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 140 Row Nuclear Medicine Pet Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 141 Row Nuclear Medicine Spect Market Revenue, by Application, 2019-2027 ($Mn)
Table 142 Row Nuclear Medicine Pet Market Revenue, by Application, 2019-2027 ($Mn)
Table 143 Row Nuclear Medicine Therapeutics Market Revenue, by Radiation Type, 2019-2027 ($Mn)
Table 144 Row Nuclear Medicine Beta Radiation Therapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 145 Row Brachytherapy Market Revenue, by Isotope, 2019-2027 ($Mn)
Table 146 Row Nuclear Medicine Therapeutics Market Revenue, by Application, 2019-2027 ($Mn)
Table 147 Row Nuclear Medicine Market Revenue, by End-Users, 2019-2027 ($Mn)
Table 148 Approvals (2019-2020)
Table 149 Collaboration (2019-2020)
Table 150 Acquisition 2018-2020
Table 151 Expansions (2019-2020)
Table 152 Others (2019-2020)
Table 153 Bayer Group: Total Revenue and R&D Expenses, 2018-2020 (Q2) ($Mn)
Table 154 Bayer Group: Total Revenue, by Segments 2018-2020 (Q2) ($Mn)
Table 155 Bayer Group: Pharmaceutical Segment Total Revenue, by Geography, 2018-2020 (Q2) ($Mn)
Table 156 Cardinal Health, Inc.: Total Revenue and R&D Expenses 2018-2020 (Q3) ($Mn)
Table 157 Cardinal Health, Inc.: Total Revenue, by Segments, 2018 -2020 (Q3) ($Mn)
Table 158 Cardinal Health, Inc.: Total Revenue, by Geography, 2018-2020 (Q3) ($Mn)
Table 159 Fujifilm Holding Corporation: Total Revenue and R&D Expenses, (2017 – 2019) ($Mn)
Table 160 Fujifilm Holding Corporation: Total Revenue, by Segments 2017-2019 ($Mn)
Table 161 Fujifilm Holding Corporation: Total Revenue, by Geography (2017 – 2019) ($Mn)
Table 162 GE Healthcare: Total Revenue and R&D Expenses 2018 – 2020 (Q2) ($Mn)
Table 163 GE Healthcare: Total Revenue, by Segments 2018-2020 (Q2) ($Mn)
Table 164 GE Healthcare: Total Revenue, by Geography (2018 –2020) (Q2) ($Mn)
Table 165 Jubilant Life Sciences: Total Revenue and R&D Expenses 2017 – 2019 ($Mn)
Table 166 Jubilant Life Sciences: Total Revenue, by Segments 2017-2019 ($Mn)
Table 167 Jubilant Life Sciences: Pharmaceutical Total Revenue, by Segments (2017-2019) ($Mn)
Table 168 Jubilant Life Sciences: Spceialty Pharmaceutical Total Revenue, by Segments (2017-2019) ($Mn)
Table 169 Jubilant Life Sciences: Total Revenue, by Geography 2017-2019 ($Bn)
Table 170 Lantheus Medical Imaging Inc.: Total Revenue and R&D Expenses, 2018-2020 (Q2) ($Mn)
Table 171 Lantheus Medical Imaging Inc.: Total Revenue, by Products 2018-2020 (Q2) ($Mn)
Table 172 Lantheus Medical Imaging Inc.: Total Revenue, by Geography 2018-2020 (Q2) ($Mn)
Table 173 Novartis International Ag: Total Revenue and R&D Expenses 2018-2020 (Q2) ($Mn)
Table 174 Novartis International Ag: Total Revenue, by Segments 2018-2020 (Q2) ($Mn)
Table 175 Novartis International Ag: Total Revenue, by Innovative Medicine Segment 2018-2020 (Q2) ($Mn)
Table 176 Novartis International Ag: Total Revenue, by Geography 2018-2020 (Q2) ($Mn)

List of Figures
Figure 1 Nuclear Medicine Global Market Share and Revenue, by Region, 2019-2027 ($Mn)
Figure 2 Research Methodology: Nuclear Medicine Global Market
Figure 3 Nuclear Medicine Global Market: Top-Down and Bottom-Up Approach
Figure 4 Nuclear Medicine Global Market: Forecasting Model
Figure 5 Nuclear Medicine Global Market: Market Crackdown and Data Triangulation
Figure 6 Nuclear Medicine Global Market: Market Segmentation
Figure 7 Diagnostics Nuclear Global Market: Market Segmentation
Figure 8 Therapeutic Nuclear Medicine Global Market: Market Segmentation
Figure 9 Stable Isotopes Global Market: Market Segmentation
Figure 10 Market Dynamics
Figure 11 Technetium-99: Supply Chain Analysis
Figure 12 Nuclear Medicine Market: Porter’S Analysis
Figure 13 Nuclear Medicine Global Market Share Analysis, by Key Players, 2020 (%)
Figure 14 Spect Isotopes: Major Player Market Share Analysis (2020) (%)
Figure 15 Pet Isotopes: Major Players Market Share Analysis (2020) (%)
Figure 16 Nuclear Medicine Therapeutic: Major Players Market Share Analysis (2020) (%)
Figure 17 Tc-99M: Major Players Market Share Analysis (2020) (%)
Figure 18 FDG: Major Players Market Share Analysis (2020) (%)
Figure 19 Ga-68: Major Players Market Share Analysis (2020) (%)
Figure 20 Rb-82: Major Players Market Share Analysis (2020) (%)
Figure 21 Nuclear Medicine Global Market Share, by Modality, 2020 V/S 2027 (%)
Figure 22 Nuclear Medicine Isotopes, by Modality
Figure 23 Spect Global Procedural Volume by Region and by Country (Nos.)
Figure 24 Tc-99M Global Procedural Volume by Region and by Country (Nos.)
Figure 25 Pet Global Procedural Volume by Region (No.S)
Figure 26 Nuclear Medicine Diagnostics Global Market Share, by Products, 2020 V/S 2027 (%)
Figure 27 Nuclear Medicine Spect Global Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 28 Nuclear Medicine Pet Global Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 29 Nuclear Medicine Spect Global Market Share, by Application, 2020 V/S 2027 (%)
Figure 30 Nuclear Medicine Spect Isotopes, by Application
Figure 31 Nuclear Medicine Pet Global Market Share, by Application, 2020 V/S 2027 (%)
Figure 32 Nuclear Medicine Pet Isotopes, by Application
Figure 33 Nuclear Medicine Therapeutics Global Market Share, by Radiation Type, 2020 V/S 2027 (%)
Figure 34 Beta Radiation Therapy Global Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 35 Nuclear Medicine Brachytherapy Global Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 36 Nuclear Medicine Therapeutics Global Market Share, by Application, 2020 V/S 2027 (%)
Figure 37 Nuclear Medicine Therapeutic Isotopes, by Application
Figure 38 Nuclear Medicine Global Market Share, by End-Users, 2020 V/S 2027 (%)
Figure 39 Stable Isotopes Market: Market Dynamics
Figure 40 Stable Isotopes Global Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 41 Stable Isotopes Global Market Share, by Application, 2020 V/S 2027 (%)
Figure 42 Stable Isotope Global Market Revenue, by Region 2019-2027 ($Mn), CAGR (%)
Figure 43 North America Stable Isotopes Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 44 North America Stable Isotopes Market Share, by Application, 2020 V/S 2027 (%)
Figure 45 Europe Stable Isotopes Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 46 Europe Stable Isotopes Market Share, by Application, 2020 V/S 2027 (%)
Figure 47 Asia-Pacific Stable Isotopes Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 48 Asia-Pacific Stable Isotopes Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 49 Rest of the World Stable Isotopes Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 50 Rest of the World Stable Isotopes Market Share, by Application, 2020 V/S 2027 (%)
Figure 51 Nuclear Medicine Global Market Revenue, by Region 2019-2027 ($Mn), CAGR (%)
Figure 52 Nuclear Medicine Global Market Share by Region and Market Revenue by Country, (2020) (%) ($Mn)
Figure 53 North America Nuclear Medicine Market Share, by Modality 2020 V/S 2027 (%)
Figure 54 North America Nuclear Medicine Diagnostic Market Share, by Product, 2020 V/S 2027 (%)
Figure 55 North America Spect Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 56 North America Pet Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 57 North America Spect Market Share, by Application, 2020 V/S 2027 (%)
Figure 58 North America Pet Market Share, by Application, 2020 V/S 2027 (%)
Figure 59 North America Therapeutic Market Share, by Radiation Type, 2020 V/S 2027 (%)
Figure 60 North America Beta Radiation Therapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 61 North America Brachytherapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 62 North America Nuclear Medicine Therapeutic Market Share, by Application, 2020 V/S 2027 (%)
Figure 63 North America Nuclear Medicine Share, by End-User, 2020 V/S 2027 (%)
Figure 64 North America Nuclear Medicine Share, by Country, 2020 V/S 2027 (%)
Figure 65 U.S. Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 66 U.S. Diagnostic Nuclear Medicine Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 67 U.S. Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 68 U.S. Pet Nuclear Medicine Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 69 U.S. Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 70 U.S. Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 71 Rest of N.A. Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 72 Rest of N.A. Diagnostic Market Revenue by Product, 2020 V/S 2027 ($Mn)
Figure 73 Rest of N.A. Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 74 Rest of N.A. Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 75 Rest of N.A. Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 76 Rest of N.A. Nuclear Medicine Market Revenue by End-User, 2020 V/S 2027 ($Mn)
Figure 77 Europe Nuclear Medicine Market Share, by Modality 2020 V/S 2027 (%)
Figure 78 Europe Nuclear Medicine Diagnostic Market Share, by Product, 2020 V/S 2027 (%)
Figure 79 Europe Spect Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 80 Europe Pet Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 81 Europe Spect Market Share, by Application, 2020 V/S 2027 (%)
Figure 82 Europe Pet Market Share, by Application, 2020 V/S 2027 (%)
Figure 83 Europe Nuclear Medicine Therapeutic Market Share, by Radiation Type, 2020 V/S 2027 (%)
Figure 84 Europe Beta Radiation Therapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 85 Europe Brachytherapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 86 Europe Nuclear Medicine Therapeutic Market Share, by Application, 2020 V/S 2027 (%)
Figure 87 Europe Nuclear Medicine Share, by End-User, 2020 V/S 2027 (%)
Figure 88 Europe Nuclear Medicine Share, by Country, 2020 V/S 2027 (%)
Figure 89 Germany Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 90 Germany Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 91 Germany Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 92 Germany Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 93 Germany Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 94 Germany Nuclear Medicine Market Revenue by End-User, 2020 V/S 2027 ($Mn)
Figure 95 France Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 96 France Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 97 France Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 98 France Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 99 France Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 100 France Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 101 Italy Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 102 Italy Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 103 Italy Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 104 Italy Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 105 Italy Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 106 Italy Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 107 Rest of E.U. Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 108 Rest of E.U. Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 109 Rest of E.U. Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 110 Rest of E.U. Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 111 Rest of E.U. Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 112 Rest of E.U. Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 113 APAC Nuclear Medicine Market Share, by Modality 2020 V/S 2027 (%)
Figure 114 APAC Nuclear Medicine Diagnostic Market Share, by Product, 2020 V/S 2027 (%)
Figure 115 APAC Nuclear Medicine Spect Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 116 APAC Nuclear Medicine Pet Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 117 APAC Nuclear Medicine Spect Market Share, by Application, 2020 V/S 2027 (%)
Figure 118 APAC Nuclear Medicine Pet Market Share, by Application, 2020 V/S 2027 (%)
Figure 119 APAC Nuclear Medicine Therapeutics Market Share, by Radiation Type, 2020 V/S 2027 (%)
Figure 120 APAC Beta Radiation Therapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 121 APAC Brachytherapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 122 APAC Nuclear Medicine Therapeutic Market Share, by Application, 2020 V/S 2027 (%)
Figure 123 APAC Nuclear Medicine Market Share, by End-User, 2020 V/S 2027 (%)
Figure 124 APAC Nuclear Medicine Market Share, by Country, 2020 V/S 2027 (%)
Figure 125 Japan Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 126 Japan Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 127 Japan Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 128 Japan Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 129 Japan Nuclear Medicine Therapeutic Market Revenue by Application (2020) ($Mn)
Figure 130 Japan Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 131 China Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 132 China Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 133 China Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 134 China Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 135 China Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 136 China Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 137 South Korea Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 138 South Korea Nuclear Medicine Diagnostic Market Revenue, by Product,2020 V/S 2027 ($Mn)
Figure 139 South Korea Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 140 South Korea Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 141 South Korea Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 142 South Korea Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 143 Rest of APAC Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 144 Rest of APAC Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 145 Rest of APAC Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 146 Rest of APAC Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 147 Rest of APAC Nuclear Medicine Therapeutic Market Revenue, by Application (2020) ($Mn)
Figure 148 Rest of APAC Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 149 Row Nuclear Medicine Market Share, by Modality 2020 V/S 2027 (%)
Figure 150 Row Nuclear Medicine Diagnostic Market Share, by Product, 2020 V/S 2027 (%)
Figure 151 Row Nuclear Medicine Spect Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 152 Row Nuclear Medicine Pet Market Share, by Isotopes, 2020 V/S 2027 (%)
Figure 153 Row Nuclear Medicine Spect Market Share, by Application, 2020 V/S 2027 (%)
Figure 154 Row Nuclear Medicine Pet Market Share, by Application, 2020 V/S 2027 (%)
Figure 155 Row Nuclear Medicine Therapeutic Market Share, by Radiation Type, 2020 V/S 2027 (%)
Figure 156 Row Beta Radiation Therapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 157 Row Brachytherapy Market Share, by Isotope, 2020 V/S 2027 (%)
Figure 158 Row Nuclear Medicine Therapeutic Market Share, by Application, 2020 V/S 2027 (%)
Figure 159 Row Nuclear Medicine Share, by End-User, (2020 Vs 2027) (%)
Figure 160 Row Nuclear Medicine Market Share, by Country, 2020 Vs 2027 (%)
Figure 161 Turkey Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 162 Turkey Nuclear Medicine Diagnostic Market Revenue by Product, 2020 V/S 2027 ($Mn)
Figure 163 Turkey Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 164 Turkey Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 165 Turkey Nuclear Medicine Therapeutic Market Revenue, by Application 2020 V/S 2027 ($Mn)
Figure 166 Turkey Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 167 Brazil Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 168 Brazil Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 169 Brazil Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 170 Brazil Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 171 Brazil Nuclear Medicine Therapeutic Market Revenue, by Application 2020 V/S 2027 ($Mn)
Figure 172 Brazil Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 173 Other Nuclear Medicine Market Revenue, by Modality, 2020 V/S 2027 ($Mn)
Figure 174 Others Nuclear Medicine Diagnostic Market Revenue, by Product, 2020 V/S 2027 ($Mn)
Figure 175 Others Nuclear Medicine Spect Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 176 Others Nuclear Medicine Pet Market Revenue, by Application, 2020 V/S 2027 ($Mn)
Figure 177 Others Nuclear Medicine Therapeutic Market Revenue, by Application 2020 V/S 2027 ($Mn)
Figure 178 Others Nuclear Medicine Market Revenue, by End-User, 2020 V/S 2027 ($Mn)
Figure 179 Key Growth Strategies (2019-2020)
Figure 180 Swot: Bayer Group
Figure 181 Swot: Bracco S.P.A
Figure 182 Swot: Cardinal Health, Inc.
Figure 183 Swot: Cdh Investments
Figure 184 Swot: Curium Pharma
Figure 185 Swot: Fujifilm Holding Corporation
Figure 186 Swot: GE Healthcare
Figure 187 Swot: Jubilant Lifesciences
Figure 188 Swot: Lantheus Medical Imaging Inc.
Figure 189 Swot: Novartis International AG

Note: Product cover images may vary from those shown

Loading
LOADING...

  • C Molecular
  • Actinium Pharmaceuticals, Inc
  • Advanced Nuclear Medicine Ingredients
  • Alpha Tau Medical
  • American Elements
  • American Radiolabeled Chemicals, Inc.
  • Arronax Cyclotron
  • Australian Nuclear Science and Technology Organization (Ansto)
  • Bayer Group
  • Beijing Zhibo Biomedical Technology Co. Ltd
  • Best Medical International, Inc
  • Board of Radiation & Isotope Technology
  • Boston Scientific Corporation (Btg International Ltd)
  • Bracco Imaging S.P.A ( Blue Earth Diagnosis)
  • Buchem B.V.
  • BV Cyclotron Vu
  • BWX Technologies (Sotera Health LLC (Nordion Inc))
  • Cambridge Isotope Laboratories, Inc. (Abx Gmbh)
  • Cardinal Health
  • Carecamp, Inc
  • CDH Investments (Sirtex Medical Ltd.)
  • Cellectar Biosciences
  • Center of Molecular Research (Cmr)
  • Centre for Probe Development and Commercialization
  • Clarity’S Pharmaceuticals
  • Curium Pharma
  • Cyclopharm Limited
  • Cyclotek
  • Diamed
  • Duchembio, Inc
  • Eckert & Ziegler Strahlen
  • Eczacibaşi-Monrol Nuclear Products
  • Eli Lilly & Co (Avid Radiopharmaceuticals)
  • Enviro
  • Eurisotop
  • Fujifilm Holdings Corporation
  • Futurechem Co. Ltd
  • Ge Company
  • Gt Medical Technologies Inc
  • Hila Pharma Ltd
  • Huayi Technology Co. Ltd (Huayi Isotopes Co)
  • Institut Radiofarmacia Aplicada De Barcelona (Iarb)
  • Institute of Isotopes
  • International Isotopes Inc.
  • Ire Elit
  • Isoaid LLC
  • Iso-Analytical Ltd.
  • Isoflex Isotope
  • Isologic
  • Isorad Ltd
  • Isoray Inc.
  • Isoscience, LLC
  • Iso-Tex Diagnostics, Inc.
  • Isotopia Molecular Imaging Ltd.
  • Ithemba Labs
  • ITM Isotopen Technologien München AG
  • JSC Isotope
  • Jubilant Lifesciences
  • Korea Atomic Energy Research Institute
  • Lantheus Medical Imaging
  • Life Molecular Imaging
  • Linde Group
  • Los Alamos National Laboratory (Lanl)
  • Medical Isotopes, Inc
  • Merck Kgaa (Sigma Aldrich-Isotec Inc)
  • Mitsubishi Chemical Holdings (Tayyo Nippon Sanso Corporation)
  • Moltek
  • Navidea Biopharmaceutical Inc.
  • Nihon-Medi Physics Co. Ltd.
  • Novartis International AG (Aaa)
  • Nuclear Research and Consultancy Group (Nrg)
  • Nukem Isotopes, GmbH
  • Omicron Biochemicals Inc
  • Orano Med (Areva Med)
  • Otsuka Pharmaceutical (Cambridge Isotope Laboratories, Inc.)
  • Pars Isotope
  • Perkinelmer Inc.
  • Perma-Fix Environmental Services, Inc. (Perma Fix Medical Sa)
  • Pet Pharm Biotech Co. Ltd
  • Polatom
  • Positron Pharma S.A.
  • QMX Laboratories
  • Radiopreparat
  • Rosatom (Jsc Isotope)
  • Rotop Pharmaka GmbH
  • Samyoung Unitech Co. Ltd
  • Saycare Therapeutics Pvt, Ltd.
  • Shanghai Gms Pharma
  • Shanghai Research Institute of Chemical Industry
  • Siemens AG
  • Solcom Limited
  • South African Nuclear Energy Corporation (Ntp)
  • Sun Pharmaceutical Industries Ltd.
  • Swan Isotopen AG
  • Telix Pharmaceuticals Limited
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd (Auspex Pharmaceuticals)
  • Theragenics Corporation
  • Theragnostics Ltd
  • Tianjin Seeds Biological Pharmacy Co. Ltd
  • Trace Sciences International
  • Urenco Stable Isotopes
  • Von Gahlen Nederland B.V.
  • Yantai Dongcheng Biochemicals Co. Ltd.
  • Zag Zyklotron AG
  • Zionexa Sas
Note: Product cover images may vary from those shown
Adroll
adroll